Management of women who have a genetic predisposition for breast cancer.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Surgical Clinics of North America

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.suc.2008.04.007PMID 18672143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast.

  2008cited by this paper
• Cancer risks among BRCA1 and BRCA2 mutation carriers

  2007cited by this paper
• Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: Recommendations of the National Society of Genetic Counselors

  2007cited by this paper
• Meta-analysis of BRCA1 and BRCA2 penetrance.

  2007cited by this paper
• Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.

  2007cited by this paper
• American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography

  2007influential reference
• Clinical practice. Management of an inherited predisposition to breast cancer.

  2007influential reference
• Founder mutations in BRCA1 and BRCA2 genes.

  2007cited by this paper
• ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes

  2006influential reference
• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  2006cited by this paper
• Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation

  2006cited by this paper
• Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2

  2006cited by this paper
• Characterization of BRCA1 and BRCA2 mutations in a large United States sample.

  2006cited by this paper
• Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.

  2006cited by this paper
• Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.

  2006cited by this paper
• ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.

  2006cited by this paper
• Clinical management of BRCA1 and BRCA2 mutation carriers

  2006cited by this paper
• Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies

  2005cited by this paper
• Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened.

  2005cited by this paper
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement

  2005cited by this paper
• Cancer screening.

  2005cited by this paper
• Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  2005cited by this paper
• Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force

  2005cited by this paper
• Hereditary cancer predisposition syndromes.

  2005cited by this paper
• Prevention and management of hereditary breast cancer.

  2005cited by this paper
• Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.

  2005cited by this paper
• The Royal Marsden Hospital pilot tamoxifen chemoprevention trial

  2004cited by this paper
• Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

  2004cited by this paper
• Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones

  2004cited by this paper
• Breast cancer screening with MRI--what are the data for patients at high risk?

  2004cited by this paper
• Recognition and management of hereditary breast cancer syndromes.

  2004cited by this paper
• BRCA1 and BRCA2: 1994 and beyond

  2004cited by this paper
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

  2004cited by this paper
• Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

  2004cited by this paper
• Screening for ovarian cancer

  2003cited by this paper
• American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

  2003cited by this paper
• Overview of the main outcomes in breast-cancer prevention trials.

  2003cited by this paper
• Screening clinical breast examination.

  2003cited by this paper
• Oophorectomy in carriers of BRCA mutations.

  2002cited by this paper
• Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

  2002cited by this paper
• Tamoxifen for breast cancer among hysterectomised women.

  2002cited by this paper
• Oophorectomy in carriers of BRCA mutations [3]

  2002cited by this paper
• Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

  2002cited by this paper
• Cancer screening

  2002influential reference
• Oophorectomy in carriers of BRCA mutations.

  2002cited by this paper
• Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

  2002cited by this paper
• Randomized trial of breast self-examination in Shanghai: final results.

  2002cited by this paper
• First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

  2002cited by this paper
• Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.

  2001cited by this paper
• Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

  2001cited by this paper
• Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary care physician

  2001cited by this paper
• Germ line mutations associated with breast cancer susceptibility.

  2001cited by this paper
• Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

  2001cited by this paper
• Common hereditary cancers and implications for primary care.

  2001cited by this paper
• Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

  2000cited by this paper
• Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.

  2000cited by this paper
• Does This Patient Have Breast Cancer? The Screening Clinical Breast Examination: Should It Be Done? How?

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How?

  1999cited by this paper
• The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives

  1999cited by this paper
• Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

  1999cited by this paper
• Tamoxifen and contralateral breast cancer.

  1999cited by this paper
• The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives

  1999cited by this paper
• [Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO)].

  1999cited by this paper
• Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

  1999cited by this paper
• Breast cancer screening 1

  1999cited by this paper
• Benefits and Risks of Screening Mammography in Women With BRCA1 and BRCA2 Mutations-Reply

  1997cited by this paper
• Reconstruction of the breast.

  1997cited by this paper
• Vaccine safety, media reporting, and Miss America.

  1997cited by this paper
• Breast cancer screening.

  1997cited by this paper
• Benefits and risks of screening mammography in women with BRCA1 and BRCA2 mutations.

  1997cited by this paper
• Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials.

  1997cited by this paper
• Benefits and risks of screening mammography in women with BRCA1 and BRCA2 mutations.

  1997cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1996cited by this paper
• Efficacy of screening mammography. A meta-analysis.

  1995cited by this paper
• Efficacy of screening mammography.

  1995cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Breast reconstruction: Surgical options and patient selection

  1994cited by this paper
• Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

  1994cited by this paper
• The rational clinical examination.

  1992cited by this paper
• Linkage of early-onset familial breast cancer to chromosome 17q21.

  1990cited by this paper
• Tamoxifen and contralateral breast cancer.

  1985cited by this paper
• IMPROVED SURVIVAL AMONGST PATIENTS TREATED WITH ADJUVANT TAMOXIFEN AFTER MASTECTOMY FOR EARLY BREAST CANCER

  1983cited by this paper
• Prostaglandin E-1 and peripheral vascular disease.

  1983cited by this paper
• Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer.

  1983cited by this paper
• Reconstruction of the breast.

  1981cited by this paper
• Breast-cancer screening.

  1979influential reference

• Complication rates among women undergoing preventive mastectomy: An Austrian registry

  2020cites this paper
• Practical consensus recommendation on when to do BRCA testing

  2018cites this paper
• Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

  2018cites this paper
• Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families

  2015cites this paper
• The case against routine preoperative breast MRI.

  2013cites this paper
• Breast cancer risk assessment, prevention, and the future.

  2013cites this paper
• THE INFLUENCE OF ENTOURAGE ON BINGE-DRINKING BEHAVIOUR IN STUDENTS

  2013influential citation
• [Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families].

  2012cites this paper
• Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families

  2011cites this paper
• A long AAAG repeat allele in the 5′ UTR of the ERR-γ gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells

  2011cites this paper
• JACÓ SARAIVA DE CASTRO MATTOS Impacto do rastreamento mamográfico em mulheres de 40 a 49 anos da região de Barretos - SP

  2011cites this paper
• A long AAAG repeat allele in the 5 0 UTR of the ERR-c gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells

  2011cites this paper
• Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery

  2010cites this paper
• Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.

  2010cites this paper
• Personalized medicine: factors influencing reimbursement.

  2010cites this paper
• The role of surgery in cancer prevention.

  2010cites this paper
• PM1 PERSONALIZED MEDICINE: FACTORS INFLUENCING REIMBURSEMENT

  2009cites this paper
• Screening and prevention of breast cancer in primary care.

  2009cites this paper
• AMWA Position Statement: Genetic Testing

  2009cites this paper